NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NBIX is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. My direct view is BUY. The stock has supportive long-term fundamentals, bullish analyst sentiment, and strong commercial momentum, while the current pre-market dip looks manageable rather than bearish. With no strong negative insider, hedge fund, or political trading signal, and with the business showing improving product traction, NBIX fits a long-term accumulation case.
NBIX is trading pre-market at 161.21, down 0.92% versus a positive S&P 500 pre-market backdrop, so the immediate tape is slightly soft. Technically, the trend is still constructive because SMA_5 > SMA_20 > SMA_200, which is a bullish moving-average structure. RSI_6 at 54.383 is neutral, so the stock is not overextended. The MACD histogram is -0.498 and negatively expanding, which suggests near-term momentum has cooled. Price is sitting just below the pivot at 161.955, with resistance at 167.882 and 171.544 and support at 156.029 and 152.367. Overall, the trend is still bullish on a medium-term basis, but short-term momentum is mixed.
["Goldman Sachs reinstated coverage with a Buy rating and $213 target after the Soleno acquisition, citing a stronger medium-term revenue growth trajectory.", "Multiple analysts raised price targets recently, including RBC, JPMorgan, Truist, Morgan Stanley, Oppenheimer, Piper Sandler, and Citi.", "Q1 results were described as strong, with Ingrezza and Crenessity both outperforming expectations.", "New clinical updates on Ingrezza showed meaningful symptom improvement and functional gains in tardive dyskinesia-related data.", "The Soleno acquisition adds a third commercial product, Vykat XR, expanding the growth base."]
["MACD is negative and weakening, signaling near-term momentum pressure.", "Pre-market price is down slightly, showing no immediate breakout enthusiasm.", "Option flow shows heavier put volume than call volume today, indicating some caution.", "RBC noted concern that Crenessity uptake may hit a near-term ceiling.", "No strong AI Stock Picker or SwingMax signal is present today."]
Financial snapshot data was not available due to an error, so I cannot assess the latest quarter figures directly from the provided snapshot. However, analyst commentary on the latest quarter indicates strong commercial performance: both Ingrezza and Crenessity exceeded expectations, and Ingrezza demand is tracking above FY26 guidance. Based on the available information, the latest quarter season appears to have been a positive growth quarter with stronger-than-expected product sales and improving revenue visibility.
Analyst sentiment is clearly positive. Recent actions show multiple Buy/Outperform/Overweight upgrades or reaffirmations with higher price targets. Goldman Sachs resumed coverage at Buy with a $213 target, Citi is at Buy with $246, Oppenheimer remains Outperform with $230, Piper Sandler is Overweight with $207, and JPMorgan/Truist are also positive. Deutsche Bank is the main holdout with a Hold rating and $155 target. Wall Street’s pros view: strong commercial momentum, successful launch traction, and a more diversified growth story after the Soleno deal. The cons view: some skepticism about how long Crenessity growth can accelerate near term and a few mixed valuation-based reservations. Overall, the Street is more bullish than bearish.
